CTOs on the Move

Doctor's Best

www.drbvitamins.com

 
We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential.   Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation.   Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.drbvitamins.com
  • 197 Avenida La Pata Suite A
    San Clemente, CA USA 92673
  • Phone: 949.498.3628

Executives

Name Title Contact Details

Similar Companies

Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics`​ specified development and commercialization participation rights.

NovoBiotic Pharmaceuticals

NovoBiotic Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inceptor Bio

Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.

Elemental Enzymes

It is widely accepted that enzyme delivery technologies are the wave of the future, they require little to no additional energy, they are widely available, and are extremely efficient. However, their use in many of today’s industrial processes is lim...

MMI Genomics

MMI Genomics is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.